Patients should be prepared to discuss medical history, current medications, previous treatments, wellness goals, and recent lab work if available
Eli Lilly (NYSE: LLY) saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron aced the Phase III ATTAIN-2 trial (NCT05872620), which assessed the small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in adults who were obese or overweight and had type 2 diabetes
Metabolic Syndrome: When GLP-1 treats metabolic syndrome diagnosed by a healthcare provider, HSA and FSA eligibility becomes more likely
Etman Gold Posted on Nov 29, 2025 Egypt 508 0 4 207 Great Verified purchase Great product from a trusted brand with a very good package and fast delivery from iHerb iHerb customer Posted on Jun 12, 2026 Australia 1 0 0 0 good product Verified purchase nice and natural and no side effects , gentle on tummy 1 2 3 4 5 9
Naturally Refreshing Taste Without Citric Acid
This marks a significant breakthrough for patients who want the benefits of GLP-1 medications without the need for weekly injections